Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.5% – Time to Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s share price traded down 4.5% during mid-day trading on Monday . The stock traded as low as $25.88 and last traded at $25.88. Approximately 142,140 shares traded hands during trading, a decline of 76% from the average daily volume of 592,123 shares. The stock had previously closed at $27.10.

Wall Street Analysts Forecast Growth

BCAX has been the subject of a number of research analyst reports. Guggenheim assumed coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Morgan Stanley raised their target price on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $30.27.

Bicara Therapeutics Stock Performance

The company has a fifty day moving average of $25.19 and a two-hundred day moving average of $21.23. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -9.37 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Equities analysts forecast that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.

Insider Activity

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $28.42, for a total value of $284,200.00. Following the completion of the sale, the chief executive officer owned 362,152 shares in the company, valued at $10,292,359.84. The trade was a 2.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares of the company’s stock, valued at $5,279,489.46. This represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 88,450 shares of company stock valued at $2,366,675. 13.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Deutsche Bank AG boosted its stake in shares of Bicara Therapeutics by 0.9% in the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after buying an additional 1,171 shares during the period. Legal & General Group Plc increased its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Mariner LLC increased its stake in Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after acquiring an additional 1,902 shares during the period. Invesco Ltd. raised its holdings in Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after acquiring an additional 1,962 shares in the last quarter. Finally, Quantinno Capital Management LP raised its holdings in Bicara Therapeutics by 16.1% in the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.